CX-5461 and Doxorubicin activate a shared DNA damage-associated transcriptional response in human cardiomyocytes
{{output}}
CX-5461 (CX) is under investigation for the treatment of late-stage cancers. While CX was first described as an RNA polymerase I inhibitor, it has recently been shown to primarily inhibit the beta isoform of topoisomerase II. This isoform is also inhibited by ... ...
